In a report released today, Madhu Kumar from Goldman Sachs maintained a Buy rating on Tricida (TCDA – Research Report), with a price target of $22.00. The company's shares closed last Wednesday at $7.46. According to TipRanks.com, Kumar is a 5-star analyst with an average return of 16.5% and a 46.7% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Iovance Biotherapeutics, and Arvinas Holding Company. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tricida with a $18.00 average price target.
https://www.tipranks.com/news/blurbs/goldman-sachs-maintains-their-buy-rating-on-tricida-tcda?utm_source=advfn.com&utm_medium=referral
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Nov 2022 até Dez 2022 Click aqui para mais gráficos Tricida.
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Dez 2021 até Dez 2022 Click aqui para mais gráficos Tricida.